ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This retrospective study analyzed data from real-world users of the MiniMed™ 780G System. Hybrid closed-loop algorithms have proven to be successful in achieving glycemic goals in people with diabetes. This performance has been consistently observed in various age groups and geographic areas.

After the introduction of the first commercial automated insulin systems in 2016, the number and variety of these devices expanded rapidly (1). This study examined real-world data from 101,629 users of the MiniMed™ 780G System in 34 countries spanning Europe, the Middle East, and Africa between 2021 and 2023. It comparing utilization rates among ideal settings, age categories, and regional/country subgroups. The mean time in range (TIR) for all users was 72.3%, the glycemic management indicator (GMI) was 7%, time < 70 mg/dL (TBR70) was 2.0%, and time < 54 mg/dL (TBR54) was 0.4%. In addition, the percentage of individuals who achieved worldwide glycemic objectives was 59.6% for GMI < 7%, 62.5% for TIR > 70%, 88.4% for TBR < 4% for 70% of the time, and 90.0% for TBR of < 1% for 54% of the time. Performance was better among users in an ideal situation; 86.3% had TIR > 70%. The average TIR in the longitudinal cohort remained > 73.3% for 12 months, while TBR70 and TBR54 fell below international targets during this period. The mean TIR was 69.9% in children aged >=15 years, who constituted 22% of the study group, and 76.8% in adults aged 56+ years, who constituted 13% of the group.

This study provides compelling evidence of the efficacy of the MiniMed™ 780G System in attaining glycemic goals among various age groups and geographical locations, based on extensive real-world data. Effort was made to overcome the study’s inability to compare diabetes subtypes, by categorizing participants by age. Nevertheless, the absence of a thorough analysis of the progressive decline in GMI, TIR, and time above range over the course of 12 months in the longitudinal sample is a notable limitation.

Reference: 1. Da Silva J, Bosi E, Jendle J, Arrieta A, Castaneda J, Grossman B, Cordero TL, Shin J, Cohen O. Real-world performance of the MiniMed™ 670G system in Europe. Diabetes Obes Metab. 2021 Aug;23(8):1942-1949.